Whistleblower News: Bristol-Myers Avoided $6.4B By Delaying Cancer Drug, US And Tennessee False Claims Act, Kodak Insider Trading

Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug

REUTERS

A new lawsuit claims Bristol-Myers Squibb Co (BMY.N) improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. read more »

United States And Tennessee File Suit Against Curo Health Services And Related Entities

DOJ

The United States and Tennessee today filed a consolidated complaint in intervention alleging violations of the False Claims Act and the Tennessee Medicaid False Claims Act by Curo Health Services Holdings, Inc., Curo Health Services, LLC, TNMO Healthcare, LLC (d/b/a Avalon Hospice), and Regency Healthcare Group, LLC, announced Acting U.S. Attorney Mary Jane Stewart for the Middle District of Tennessee and Tennessee Attorney General Herbert Slatery III.  The complaint also states common law claims, including unjust enrichment and payment under mistake of fact. read more »

NY attorney general James demands Kodak CEO testify on alleged insider trading

CNBC

The New York Attorney General on Tuesday asked a court to force Kodak’s CEO to publicly testify amid an investigation over allegations of insider tradingread more »